Atlas Trials

hATTR Amyloidosis

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch hATTR Amyloidosis

RecordFirmDate
Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ). (NCT03728634)Ionis Pharmaceuticals, Inc.2018-12-21

Track hATTR Amyloidosis automatically

Every clearance here is in the API, with alerts when new ones post.